Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: A retrospective evaluation

Journal of Clinical Psychopharmacology

Volumn 34, Issue 5, 2014, Pages 559-564

  Cameron, Colin ^a   Watson, Diane ^a   Robinson, Jeffrey ^a  

^a ROYAL OTTAWA HEALTH CARE GROUP   (Canada)

Author keywords

chronic pain; harm reduction; PTSD related insomnia and nightmares; seriously mentally ill offenders; synthetic cannabinoid nabilone

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; HYPNOTIC SEDATIVE AGENT; NABILONE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; CANNABINOID; DRONABINOL;

ABDOMINAL CRAMP; ADULT; ANOREXIA; ARTICLE; CANNABIS ADDICTION; CHRONIC PAIN; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; GLOBAL ASSESSMENT OF FUNCTIONING; HARM REDUCTION; HEADACHE; HIGH RISK POPULATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NIGHTMARE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; POLYPHARMACY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RESTLESSNESS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SLEEP QUALITY; SLEEP TIME; TINNITUS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; XEROSTOMIA; ANALOGS AND DERIVATIVES; COMPLICATION; DREAM; DRUG EFFECTS; MIDDLE AGED; PRISONER; PSYCHOLOGY; SLEEP INITIATION AND MAINTENANCE DISORDERS; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; CANNABINOIDS; CHRONIC PAIN; DREAMS; DRONABINOL; HARM REDUCTION; HUMANS; MALE; MIDDLE AGED; PRISONERS; RETROSPECTIVE STUDIES; SLEEP INITIATION AND MAINTENANCE DISORDERS; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84907423668     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000180     Document Type: Article

References (21)

1. Earlywine M. Chapter 1: Highlights in the history of cannabis. In: Understanding Marijuana: A New Look at the Scientific Evidence. Oxford: Oxford University Press; 2002;3-28.
2. Grotenhermen F, Muller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int. 2012;109;29-30:495-501.
3. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol. 2006;105;1-2:1-25.
4. Repchinsky C. Compendium of Pharmaceuticals & Specialities. Ottawa, Ontario, Canada: Canadian Pharmacists Association; 2013.
5. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain: A systematic review of randomized trials. Br J Clin Pharmacol. 2011;72(5):735-744.
6. Burns TL, Ineck JR. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother. 2006;40(2):251-260.
7. Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther. 2009;15(1):84-88.
8. Lile JA, Kelly TH, Hays LR. Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating delta-9-tertrahydrocannabinol. Clin Neuropharmacol. 2012;33(5):235-242.
9. Ware MA, St Armand E. The abuse potential of the synthetic cannabinoid nabilone. Addiction. 2010;105(3):494-503.
10. Sv́zenská I, Dubov P, Sulcová A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structuresYa short review. Pharmacol Biochem Behav. 2008;90(4):501-511.
11. Hill MN, Bierer LM, Makotkine I, et al. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology. 2013;38(12):2952-2961.
12. Jiang W, Zhang Y, Xiao L, et al. Cannabinoids promote embryonic and adult hippocampal neurogenesis and produce anxiolytic and antidepressant-like effect. J Clin Invest. 2005;115(11):3104-3116.
13. Bremner JD, Randall P, Scott TM, et al. MRI-based measurements of hippocampal volume in combat-related post-traumatic stress disorder. Am J Psychiatry. 1995;152:973-978.
14. Gilbertson MW, Shenton ME, Ciszewski A, et al. Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. Nat Neurosci. 2002;5:1242-1247.
15. Gurvits TV, Shenton ME, Hokama H, et al. Magnetic resonance imaging study of hippocampal volume in chronic, combat-related post-traumatic stress disorder. Biol Psychiatry. 1996;40:1091-1099.
16. Goff A, Rose E, Rose S, et al. Does PTSD occur in sentenced prison populations? A systematic review. Crim Behav Ment Health. 2007;17:152-162.
17. Maher MJ, Rigo SA, Asnis GM. Sleep disturbances in patients with posttraumatic stress disorder: Epidemiology, impact and approaches to management. CNS Drugs. 2006;20(7):567-590.
18. Fazel S, Bains P, Doll H. Substance abuse and dependence in prisoners: A systematic review. Addiction. 2006;101(2):181-191.
19. Pacella ML, Hruska B, Delahanty DL. The physical health consequences of PTSD and PTSD symptoms: A meta-analytic review. J Anxiety Disord. 2012;13(27):33-46.
20. Swartz JA. Chronic medical conditions among jail detainees in residential psychiatric treatment: A latent class analysis. J Urban Health. 2011;88(4):700-717.
21. Weathers FW, Litz BT, Huska JA, et al. Posttraumatic Checklist Civilian Version (PCL-C). National Centre for PTSDVBehavioural Science Division. 1994. Available at: http://www.mirecc.va.gov/docs/visn6/3-PTSD-CheckList-and-Scoring. pdf. Accessed February 22, 2014.